This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hermani, A. Articles by Mayer, D. Search for Related Content PubMed PubMed Citation Articles by Hermani, A. Articles by Mayer, D.

Calcium-Binding Proteins S100A8 and S100A9 as Novel Diagnostic Markers in Human Prostate Cancer

Authors' Affiliations: ¹ Research Group Hormones and Signal Transduction and ² Division of Signal Transduction and Growth Control, German Cancer Research Center, Heidelberg, Germany; and Departments of ³ Pathology, and ⁴ Urology, University Hospital Mannheim, University of Heidelberg, Mannheim, Germany

Requests for reprints: Doris Mayer, Research Group "Hormones and Signal Transduction," Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. Phone: 49-6221-423238; Fax: 49-6221-423237; E-mail: d.mayer{at}dkfz-heidelberg.de.

Purpose: S100 proteins comprise a family of calcium-modulated proteins that have recently been associated with epithelial tumors. We examined the expression of two members of this family, S100A8 and S100A9, together with the S100 receptor RAGE (receptor for advanced glycation end products) in human prostate adenocarcinomas and in prostatic intraepithelial neoplasia.

Experimental Design: Tissue specimens of 75 patients with organ-confined prostate cancer of different grades were analyzed by immunohistochemistry for expression of S100A8, S100A9, and RAGE. In addition, in situ hybridization of S100A8 and S100A9 was done for 20 cases. An ELISA was applied to determine serum concentrations of S100A9 in cancer patients compared with healthy controls or to patients with benign prostatic hyperplasia (BPH).

Results: S100A8, S100A9, and RAGE were up-regulated in prostatic intraepithelial neoplasia and preferentially in high-grade adenocarcinomas, whereas benign tissue was negative or showed weak expression of the proteins. There was a high degree of overlap of S100A8 and S100A9 expression patterns and of S100A8 or S100A9 and RAGE, respectively. Frequently, a gradient within the tumor tissue with an increased expression toward the invaded stroma of the prostate was observed. S100A9 serum levels were significantly elevated in cancer patients compared with BPH patients or healthy individuals.

Conclusion: Our data suggest that enhanced expression of S100A8, S100A9, and RAGE is an early event in prostate tumorigenesis and may contribute to development and progression or extension of prostate carcinomas. Furthermore, S100A9 in serum may serve as useful marker to discriminate between prostate cancer and BPH.

This article has been cited by other articles:

				P. Sinha, C. Okoro, D. Foell, H. H. Freeze, S. Ostrand-Rosenberg, and G. Srikrishna Proinflammatory S100 Proteins Regulate the Accumulation of Myeloid-Derived Suppressor Cells J. Immunol., October 1, 2008; 181(7): 4666 - 4675. [Abstract] [Full Text] [PDF]

				O. Turovskaya, D. Foell, P. Sinha, T. Vogl, R. Newlin, J. Nayak, M. Nguyen, A. Olsson, P. P. Nawroth, A. Bierhaus, et al. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis Carcinogenesis, October 1, 2008; 29(10): 2035 - 2043. [Abstract] [Full Text] [PDF]

				H. Gu, L. Yang, Q. Sun, B. Zhou, N. Tang, R. Cong, Y. Zeng, and B. Wang Gly82Ser Polymorphism of the Receptor for Advanced Glycation End Products Is Associated with an Increased Risk of Gastric Cancer in a Chinese Population Clin. Cancer Res., June 1, 2008; 14(11): 3627 - 3632. [Abstract] [Full Text] [PDF]

				H. Y. Sroussi, J. Berline, and J. M. Palefsky Oxidation of methionine 63 and 83 regulates the effect of S100A9 on the migration of neutrophils in vitro J. Leukoc. Biol., March 1, 2007; 81(3): 818 - 824. [Abstract] [Full Text] [PDF]